Literature DB >> 24666837

Is dexmedetomidine superior to midazolam as a premedication in children? A meta-analysis of randomized controlled trials.

Yu Sun1, Yi Lu, Yan Huang, Hong Jiang.   

Abstract

BACKGROUND: In the current published literature, there are controversial results regarding the effectiveness of dexmedetomidine compared with midazolam as premedication in children. The aim of this meta-analysis was to compare the use of dexmedetomidine as a premedication in pediatric patients with that of midazolam.
METHODS: We searched for articles published in English that matched the key words 'dexmedetomidine', 'midazolam', and 'children' in the PubMed, Cochrane Library, Ovid, and Google Scholar databases. Additional studies were identified from the reference lists of the retrieved articles. Only prospective randomized controlled trials (RCTs) that compared the use of dexmedetomidine and midazolam as premedications in children were included. The extraction of data from the articles was performed independently by two authors using a predesigned Excel spreadsheet. The relative risks (RRs), weighted mean differences (WMDs), and their corresponding 95% confidence intervals (95% CIs) were calculated for dichotomous and continuous outcome data using the quality effects model of the MetaXL version 1.3 software.
RESULTS: Eleven prospective RCTs (829 children) met our criteria. Compared with midazolam, dexmedetomidine premedication was associated with more satisfactory sedation upon parent separation (eight RCTs [679 children]; RR: 1.25; 95% CI: 1.06, 1.46) and upon mask acceptance (seven RCTs [559 children]; RR: 1.17; 95% CI: 1.01, 1.36). During the postoperative period, premedication with dexmedetomidine lowered the numbers of requests for rescue analgesia (six RCTs [477 children]; RR: 0.55; 95% CI: 0.40, 0.74) and lowered the risks of agitation or delirium (seven RCTs with [466 children]; RR: 0.59; 95% CI: 0.40, 0.88), and shivering (three RCTs [192 children]; RR: 0.33; 95% CI: 0.18, 0.61). However, dexmedetomidine premedication reduced systolic blood pressure (three RCTs [242 children]; WMD: -11.47 mm·Hg(-1) ; 95% CI: -13.95, -8.98), mean blood pressure (three RCTs [202 children]; WMD: -5.66 mm·Hg(-1) ; 95% CI: -8.89, -2.43), and heart rate (six RCTs [444 children]; WMD: -12.71 beat·min(-1) ; 95% CI: -14.80, -10.62), and prolonged the onset of sedation (two RCTs [132 children] WMD: 13.78 min; 95% CI: 11.33, 16.23; I(2) = 0%) relative to midazolam.
CONCLUSION: This meta-analysis demonstrated that dexmedetomidine premedication is superior to midazolam premedication in terms of producing satisfactory sedation upon parent separation and mask acceptance. Dexmedetomidine premedication provides clinical benefits that included reducing the requirements for rescue analgesia and reducing agitation or delirium and shivering during the postoperative period. However, the risks of heart rate and blood pressure decreases, and the prolonged onset of sedation associated with dexmedetomidine should be considered.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  children; dexmedetomidine; midazolam; premedication; quality effects

Mesh:

Substances:

Year:  2014        PMID: 24666837     DOI: 10.1111/pan.12391

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  19 in total

Review 1.  Dexmedetomidine for antiemesis in gynecologic surgery: a meta-analysis of randomized controlled trials.

Authors:  Wei-Guo Zhong; Xin-Yu Ge; Hai Zhu; Xiao Liang; Hong-Xia Gong; Ming Zhong; Xiang Xiao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Systematic review and meta-analysis comparing the efficacy of dexmedetomidine to midazolam as premedication and a sedative agent in pediatric patients undergoing dental procedures.

Authors:  Saumya Taneja; Anuj Jain
Journal:  Oral Maxillofac Surg       Date:  2022-06-27

3.  Efficacy of dexmedetomidine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials.

Authors:  Xiao Liang; Miao Zhou; Jiao-Jiao Feng; Liang Wu; Shang-Ping Fang; Xin-Yu Ge; Hai-Jing Sun; Peng-Cheng Ren; Xin Lv
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Dexmedetomidine versus midazolam for sedation during endoscopy: A meta-analysis.

Authors:  Fan Zhang; Hao-Rui Sun; Ze-Bing Zheng; Ren Liao; Jin Liu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

5.  Efficacy of dexmedetomidine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials.

Authors:  Xiao Liang; Miao Zhou; Jiao-Jiao Feng; Liang Wu; Shang-Ping Fang; Xin-Yu Ge; Hai-Jing Sun; Peng-Cheng Ren; Xin Lv
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Comparison of single minimum dose administration of dexmedetomidine and midazolam for prevention of emergence delirium in children: a randomized controlled trial.

Authors:  Eun-Ah Cho; Yun-Byeong Cha; Jae-Geum Shim; Jin-Hee Ahn; Sung Hyun Lee; Kyoung-Ho Ryu
Journal:  J Anesth       Date:  2019-11-07       Impact factor: 2.078

7.  Anesthesia awareness. Can midazolam attenuate or prevent memory consolidation on intraoperative awakening during general anesthesia without increasing the risk of postoperative delirium?

Authors:  Marco Cascella
Journal:  Korean J Anesthesiol       Date:  2015-04

8.  Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery.

Authors:  Seyedeh Zahra Faritus; Mehrdad Khazaee-Koohpar; Mohsen Ziyaeifard; Mohammad Javad Mehrabanian
Journal:  Anesth Pain Med       Date:  2015-06-22

9.  Routines for reducing the occurrence of emergence agitation during awakening in children, a national survey.

Authors:  Pether K Jildenstål; Narinder Rawal; Jan L Hallén; Lars Berggren; Jan G Jakobsson
Journal:  Springerplus       Date:  2014-09-30

10.  Effects of dexmedetomidine versus midazolam for premedication in paediatric anaesthesia with sevoflurane: A meta-analysis.

Authors:  Ji-Feng Feng; Xiao-Xia Wang; Yan-Yan Lu; Deng-Ge Pang; Wei Peng; Jian-Lan Mo
Journal:  J Int Med Res       Date:  2017-04-20       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.